TEST:

OncoCompass™ Target

"NeoGenomics, Inc...will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting, booth #2347, in San Diego, December 7-10. The company will also feature its robust hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel."

Excellent reproducibility was observed with complete concordance for all samples performed in replicates. Conclusions The urine-based OncoCompass Target TM deep-sequencing assay has demonstrated robust sensitivity for low-frequency SNVs, indels, and fusions, offering an opportunity for non-invasive diagnostics and treatment response monitoring in patients with UBC.

The EGFRexon20ins concordance between tumor tissue-based and plasma ctDNA testing is high. Antitumor activity of sunvozertinib was robust regardless of tumor tissue-based or plasma ctDNA tests. Both tests can be applied for identifying patients who potentially benefit from sunvozertinib treatment.

"Burning Rock Biotech Limited...announced a strategic partnership with Merck KGaA, Darmstadt, Germany, in companion diagnostics (CDx) development for the MET inhibitor tepotinib in the mainland China market. The CDx test is based on Burning Rock's self-developed next generation sequencing (NGS)-based liquid biopsy solution, OncoCompass Target™ panel....Tepotinib was the first oral MET inhibitor to receive a regulatory approval anywhere in the world for the treatment of advanced non-small cell lung cancer (NSCLC) harboring MET gene alterations..."

Investor Presentation